Precision medicine starts with the patient-physician relationship, and this also involves an entire care team, emphasized Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.
Precision medicine starts with the patient-physician relationship, but it also includes identifying the right laboratory to answer the clinical question at hand and being comfortable with discussing molecular testing, which involves an entire care team, emphasized Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.
Transcript
Can you discuss the role of a patient navigator for patients currently receiving or set to receive targeted treatment for cancer?
I wish there was such an individual that exists. Ultimately, a cancer patient typically is advocated [for] by their oncology care team that is led by the oncologist. The unfortunate truth of that is that much of the precision medicine interaction starts with the patient-physician relationship: identifying the right patient for the right test at the right time in their treatment trajectory.
Once that has taken place, still a whole host of different things needs to happen, from which laboratory do I utilize to answer the clinical question that I have in front of me to identify a target that could potentially help me change the trajectory of my care plan for that patient, because I am finding a target that I can potentially treat with the medication that is utilizing that particular target. And so a champion in that regard would be somebody who is very comfortable in the environment of discussing molecular testing, which is a very complex concept, with their oncology patient and has the expertise of knowing which laboratory will provide the right test from the right material—Is it tumor tissue? Is it blood, like a liquid biopsy? Is it saliva?—whatever it might be, to answer the clinical question on hand and furthermore has the logistical wherewithal in their office to know how to order the test?
Do I need to log on to a portal? Is there a paper requisition that needs to be faxed to the laboratory? And then with all that comes a whole host of other supportive staff that now needs to make sure that the specimen gets sent from the pathology laboratory to the testing laboratory, is received in the testing laboratory, the quality control has happened there, the specimen is sufficient for testing, then the result is received back with the physician, has been acknowledged by the physician and translated into a discussion at the bedside with the patient.
Not to even let alone that these results are super complex and may result in, yes, actionable mutations that the physician may be very familiar with and know what to do with, but it may also be a lot of what we call garbage or, you know, white noise. Lots of information on mutations or variations of unknown significance that may actually not influence the trajectory of the treatment, but may very well take away valuable time in the visit with the patient for the physician to explain, “Well, here's what the result means, and unfortunately, it's not actionable.”
So long-winded answer to your short question, who is the champion? It's not a one-person deal. It's a team effort that starts with the patient-physician relationship, but involves an entire care team, the logistical sort of staff that needs to be in place in order for all this to work.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More